Current evidence to support extensive use of probiotics in inflammatory bowel disease is 20 limited and factors contribute to the inconsistent effectiveness of clinical probiotic therapy are 21 not completely known. Here, as a proof-of-concept, we utilized Bifidobacterium longum JDM 22 301, a widely used commercial probiotic strain in China, to study potential factors that may 23 influence the beneficial effect of probiotics in experimental colitis. We found that the probiotic 24 therapeutic effect was varied across individual mouse even with the same genetic background 25 and consuming the same type of food. The different probiotic efficacy was highly correlated 26 with different microbiome features in each mouse. Consumption of a diet rich in fat can change 27 the host sensitivity to mucosal injury-induced colitis but did not change the host responsiveness 28 to probiotic therapy. Finally, the host genetic factor TLR2 was required for a therapeutic effect 29 of B. longum JDM 301. Together, our results suggest that personalized microbiome and genetic 30 features may modify the probiotic therapeutic effect.
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After the mice were pretreated with B. longum JDM 301, the body weight loss was 148 minimized and the colon shrinking was reduced in cohort A compared to those treated only 149 with DSS, while mice in cohort B did not show any sign of colitis improvement with probiotic 150 treatment ( Fig 1C and 1D) . Microscopically, colonic epithelial damage and inflammatory cell 151 infiltration were reduced in cohort A mice that were treated with B. longum JDM 301, while 152 severe epithelial damage and inflammation remained in cohort B mice (Fig 1E and 1F) . The 153 data implied that the host microbiota not only influences IBD pathogenesis, it also influences 154 the therapeutic effect of probiotics.
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The therapeutic effect of the probiotic B. longum JDM 301 in IBD is not correlated with treatment ( Fig 5C and 5D) . The data imply a requirement of intact TLR2 signals in establishing In this work, we measured the ability of gut microbiota, high-fat diet and host genetic factor 244 (e.g. TLR2) to influence the host response to a model probiotic, B. longum JDM 301, in a DSS-245 induced mouse colitis model. We demonstrated that the probiotic therapeutic effect can be 246 varied across individual mouse even when the mice have the same genetic background and 247 consume the same type of food. We further showed different microbiome features were highly 248 correlated with different probiotic response. Consumption of diet rich in fat can change the host 249 sensitivity to mucosal injury-induced colitis, but may not necessarily change the host 250 responsiveness to probiotic therapy. Finally, the host genetic factor TLR2 was also required for 251 a therapeutic effect of B. longum JDM 301.
252
Although probiotics are defined as beneficial microorganisms to the host, exact 253 mechanisms of how probiotics function between the host and the gut microbiome remain 254 incompletely understood. The bacterial species that can be called probiotics are still expanding 255 (28), but whether one type of probiotic fits for all people at the same or different disease 256 conditions is currently not clear. Our data suggested that the individual host gut microbiome 257 can probably influence whether a given probiotic can have beneficial effects on the specific 258 host or not. Possible pathways that have been suggested for how probiotics works include: (i) How personalized microbiome influence probiotic effect requires further investigation. One 263 possible influence of the host microbiome is to influence the probiotic engraftment efficacy 264 (30-32). Another possible influence of the microbiome to the probiotics is to influence their 265 functions. One earlier study indicated that when the gut microbes translocated to the internal 266 tissue, they can induce disease tolerance (33). Many other more possible mechanisms remain to 267 be determined.
268
Our data further suggested that it might be possible to predict probiotic efficacy via analysis 269 of the host microbial and genetic features. Personalized measurements including gut 270 microbiome have been shown to be able to more accurately predict postprandial glycemic 271 response for each unique person (34), it might also help for personalized probiotic therapies.
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In aggregate, this study demonstrated correlation of individual host microbiome and 
